Development of CMTM6 inhibitors: Modulation of PDL1 for cancer treatment
Reference number | |
Coordinator | Adlego Biomedical AB |
Funding from Vinnova | SEK 142 550 |
Project duration | March 2018 - January 2020 |
Status | Completed |
Venture | Eurostars |
Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.
You're using version {0} of the web browser {1}. This means that the content or functionality of our website may be limited or unavailable. We recommend that you upgrade your browser to optimise your experience of our website.
Development of CMTM6 inhibitors: Modulation of PDL1 for cancer treatment
Reference number | 2018-00582 |
Coordinator | Adlego Biomedical AB |
Funding from Vinnova | SEK 142 550 |
Project duration | March 2018 - January 2020 |
Status | Completed |
Venture | Eurostars |
Last updated 20 March 2019
Reference number 2018-00582